Search tips
Search criteria 


Logo of jneuromotThis ArticleAims and ScopeInstructions to AuthorsE-SubmissionJournal of Neurogastroenterology and Motility
J Neurogastroenterol Motil. 2010 January; 16(1): 8–21.
Published online 2010 January 31. doi:  10.5056/jnm.2010.16.1.8
PMCID: PMC2879816

Nonerosive Reflux Disease (NERD) - An Update


Recognizing nonerosive reflux disease (NERD) as a distinct presentation of gastroesophageal reflux disease (GERD) was one of the most important developments in the field of GERD in the last decade. Whilst the definition of NERD has not changed significantly over the years, the disorder accounts for the majority of the GERD patients and those who failed proton pump inhibitor (PPI) treatment. Recent developments in NERD focused primarily on understanding the pathophysiology and natural history. The introduction of esophageal impedance + pH has led to the assessment of other forms of gastroesophageal reflux in causing NERD. Therapeutic modalities still focus on acid suppression, but there is growing recognition that other therapeutic strategies should be considered in NERD.

Keywords: Nonerosive reflux disease, Gastroesophageal reflux disease, Proton pump inhibitor


It has been demonstrated that 44% of the US population report gastroesophageal reflux disease (GERD)-related symptoms at least once a month and 20% once a week.1,2 Furthermore, due to the close relationship between GERD and body mass index (BMI), it is highly likely that the prevalence of GERD will closely follow the increase in BMI that is expected in the future.

Most of the patients with GERD fall into 1 of 2 categories: nonerosive reflux disease (NERD) or erosive esophagitis. The 2 main phenotypes of GERD appear to have different pathophysiological and clinical characteristics. Furthermore, NERD and erosive esophagitis clearly diverge when it comes to response to antireflux treatment. NERD patients have a significantly lower response rate to proton pump inhibitor (PPI) therapy, and consequently they constitute the majority of the refractory heartburn group.3,4


NERD has been commonly defined as the presence of classic GERD symptoms in the absence of esophageal mucosal injury during upper endoscopy. The Genval workshop suggested that the definition of NERD should be reserved for individuals who satisfy the definition of GERD but who do not have either Barrett's esophagus or definite endoscopic esophageal mucosal breaks (erosion or ulceration).5 We proposed that NERD should be defined as the presence of typical symptoms of gastroesophageal reflux disease caused by intraesophageal reflux (acidic or weakly acidic), in the absence of visible esophageal mucosal injury at endoscopy.1

Recently, the Montreal International Consensus defined GERD as a condition that develops when the reflux of stomach contents causes troublesome reflux-associated symptoms, and NERD was defined by the presence of these symptoms in the absence of esophageal mucosal breaks.6

Studies have shown that about 30-50% of NERD patients demonstrate esophageal acid exposure within the physiological range.7 The Rome II Committee for Functional Esophageal Disorders considered these patients as having functional heartburn, defined as "episodic retrosternal burning in the absence of pathological gastroesophageal reflux, pathology-based motility disorders, or structural explanations."8 This subgroup was further divided into 2 subgroups. The first subgroup included patients who demonstrated a close temporal relationship between their heartburn symptoms and acid reflux events, in spite of having physiological range of esophageal acid exposure. This subgroup accounts for up to 40% of patients with functional heartburn and has been termed the hypersensitive esophagus.7 Patients with hypersensitive esophagus demonstrate partial response to PPI treatment.9 In contrast, the other subgroup (up to 60%) demonstrates lack of any correlation between heartburn episodes and acid reflux events. The Rome III Committee for Functional Esophageal Disorders redefined the functional heartburn group, and consequently NERD, by primarily incorporating the hypersensitive esophagus group and those patients with negative symptom association who are responsive to PPI treatment back into the NERD group (Fig. 1).10

Figure 1
A diagnostic algorithm for NERD and functional heartburn based on Rome III criteria.10


Several early studies reported that about 50% of patients with heartburn were found to exhibit normal esophageal mucosa during endoscopy.11,12 There after, several community-based European studies of NERD patients found a much higher prevalence of up to 70%.13,14 Galmiche et al.15 assessed the efficacy of on-demand H2RA therapy in patients with GERD symptoms who were recruited from general practice clinics. A total of 423 GERD patients were included in this study; and, of those, 71% met the criteria for NERD. Carlsson et al.16 compared different treatment strategies for GERD at 36 primary care centers in Europe and Australia and noted that 49% of the 538 enrolled patients lacked esophageal mucosal breaks.

In the United States, Robinson et al.17 evaluated only subjects who used antacids for symptomatic relief of heartburn. Of 165 patients enrolled in this study, 53% had normal esophageal mucosa on upper endoscopy. In a recent population-based study, 1,000 subjects with or without GERD-related symptoms from an adult population of 2 Swedish municipalities were randomly selected to undergo an upper endoscopy. Of the patients with gastroesophageal reflux symptoms, only 24.5% were found to have erosive esophagitis.18 More recently, Zagari et al. performed a large epidemiologic study in the general population of 2 villages in northern Italy and demonstrated a 23.7% (out of 1,033 subjects) prevalence rate of patients with reflux symptoms at least twice a week. Of those patients with reflux symptoms, 75.9% were found to have a negative endoscopy.19

Overall, the results of old and recent epidemiologic studies investigating patients with GERD-related symptoms have suggested that the prevalence of NERD in the general population is between 50% and 70%. Because the usage of proton pump inhibitors (PPIs) has become so widespread, it is likely that some of the recent studies that determined the prevalence of NERD have been contaminated by including healed erosive esophagitis subjects as NERD patients.

Natural History

Within the spectrum of GERD, the pathophysiological relationship between NERD and erosive esophagitis remains the subject of great debate.20 The assumption that NERD and erosive esophagitis represent 1 continuous disorder has been challenged by studies demonstrating differences in relation to epidemiological features, pathophysiological characteristics, and responses to treatment.21-23

Pace et al.24 performed a retrospective evaluation of patients with NERD. The authors followed 33 patients with NERD and documented abnormal esophageal pH monitoring for a period of 3-6 months while on therapy with antacids, prokinetics or both. Five (15%) of the patients that remained symptomatic during therapy developed erosive esophagitis (unknown grading). Pretreatment pH testing results were not predictable of erosive esophagitis development. In this study, patients were treated from the time of admittance into the study, suggesting that some may have not been true NERD patients. Furthermore, the observation in the study that NERD patients rapidly progressed to develop erosive esophagitis after only a very short duration of follow-up (3-6 months) may further support the conclusion that those who developed erosive esophagitis during the study period were likely healed erosive esophagitis patients that were falsely labeled as having NERD from the beginning.

Kuster et al.25 followed 109 patients with GERD, of whom 33 had endoscopically documented erosive esophagitis. The authors used a step-up approach in which patients initially received antacids and prokinetics, and if symptoms continued an H2RA was prescribed. Patients that did not respond to an H2RA were referred for antireflux surgery. At the 3-year follow-up, 109 patients were available for evaluation, and of those 52% required only antacids plus prokinetics to control their symptoms. At the 6-year follow-up, 89 patients were available for evaluation, and of those 55% required only antacids plus prokinetics to control their symptoms. Regardless of therapy, only 2.7% of the NERD patients developed erosive esophagitis after 3 years and 3% after 6 years of follow-up. Unlike Pace et al.,24 this study provided longer duration of follow-up, and despite its limitations very few NERD patients progressed to develop esophageal mucosal injury. Isolauri et al.26 conducted a longer duration follow-up (17-22 years, mean 19.5 years) of 60 patients with documented GERD. Patients received medical (50) or surgical (10) antireflux therapy as needed (no standardization). Of the 50 subjects that received only medical therapy, 30 had NERD and 20 erosive esophagitis at baseline. At follow-up, only 5 (17%) of the NERD patients progressed to develop erosive esophagitis (all to grade 1 Savary-Miller).

McDougall et al.27 conducted a 10 year follow-up of 152 patients with typical GERD symptoms and grade 1-3 erosive esophagitis (modified Savary-Miller) documented during an upper endoscopy. Over 70% of the patients still had heartburn daily or at least weekly at follow-up. Patients reporting dysphagia underwent repeat endoscopy, revealing 2 new benign peptic strictures and 1 Barrett's esophagus. However, because this was a survey study and patients were allowed to be on and off treatment ad libitum, it is difficult to interpret the findings. Furthermore, the presence of so-called "new Barrett's esophagus" may well be an unrecognized Barrett's mucosa that was present underneath esophageal inflammation. In another study, McDougall et al.28 performed a prospective follow-up of 101 GERD patients for a period of at least 32 months after initial assessment with pH testing and an upper endoscopy. During follow-up, more than half of the patients were on a PPI or H2RA. Of the 17 subjects with NERD and abnormal pH testing, 4 (24%) developed erosive esophagitis while on H2RA. Again, the authors' report in this study that 3 patients with erosive esophagitis developed Barrett's esophagus may also represent an unrecognized Barrett's mucosa that was present underneath the esophageal inflammation.

Manabe et al.29 followed 105 patients with mild erosive esophagitis (Los Angeles classification A and B) for a mean duration of 5.5 years. Only 10.5% of the patients progressed to higher grading (mostly Los Angeles grade C), and none have progressed to Barrett's esophagus. This study suggests that even within the different gradings of erosive esophagitis, there is very little progression over time.

Two recent retrospective studies stand out in their findings about the natural course of GERD. Unlike the aforementioned studies as well as other more recently published articles (vide infra), Pace et al.30 have reported a 94% progression of NERD to erosive esophagitis. Using their original cohort of GERD subjects,24 the authors were able to endoscope 18 of 33 subjects. Seventeen (94%) were found to have esophageal mucosal inflammation (erosive esophagitis). The authors concluded that GERD is a chronic disease characterized by increasing severity in time, requiring protracted medical therapy. Although the authors provide only 2 endoscopies (index and follow-up), they concluded that almost all NERD patients are destined to progress over time to develop erosive esophagitis, regardless of the extent of their esophageal acid exposure.31 The study does not provide evidence of increased severity in gastroesophageal reflux that parallels the new endoscopic findings. In contrast to the previous study, Labenz et al. have recently proposed a highly complex model to describe the natural course of GERD.32 Using the ProGERD (progression of gastroesophageal reflux disease) database, the authors evaluated progression or regression in GERD. Interestingly, the study demonstrated significant progression and regression after 2 years of follow-up.31 The authors showed that 24.9% of the NERD patients progressed to develop low-grade erosive esophagitis (Los Angeles classification grades A and B), and 0.6% developed severe erosive esophagitis (Los Angeles classification grades C and D). Surprisingly, 50.4% of those with grades C and D and 61.3% with grades A and B regressed to NERD. Again, the study provides only 2 endoscopies (index and follow-up), and thus the durability of the described esophageal mucosal findings is unknown. Furthermore, 73% of the subjects in this study had taken antireflux medications, and 61% had visited a physician.33 The study suggests for the first time that patients move freely and in large numbers from NERD to erosive esophagitis and back again.

Garrido Serrano et al. followed 692 GERD patients over a period of 6 years and prospectively assessed progression or regression along the spectrum.34 The authors found that patients with NERD (50% of the sample) did not develop erosive esophagitis and those with erosive esophagitis remained within the stage of the initial diagnosis. Sontag et al.35 evaluated 4,633 patients undergoing endoscopy for reflux symptoms over a mean follow-up period of 7.6 years. The patients received antireflux medications, but treatment regimens were not standardized for all patients. The authors were unable to document progression of NERD along the spectrum. Bardhan et al. provided the longest and largest natural history data evaluating 12,374 GERD patients over a period of 24 years.36 The authors were able to document only 4.4% progression to erosive esophagitis among the NERD patients.

Overall, the currently available natural course studies suggest that lack of progression is more common than progression along the spectrum for patients with NERD (Table 1). Most importantly, there is no evidence that NERD patients may progress over time to develop Barrett's esophagus.

Table 1
The Largest Population-based Studies Assessing Progression of NERD to Erosive Espophagitis23

Fass and Ofman22 proposed a novel paradigm suggesting that GERD patients exhibit 3 phenotypic presentations: NERD erosive esophagitis, and Barrett's esophagus. The vast majority of NERD and erosive esophagitis patients remain within their respective GERD groups throughout their lifetime. This new paradigm proposes that the genetic makeup of each individual subject exposed to similar environmental factors may ultimately determine the specific phenotypic presentation of GERD (Fig. 2).22,23 In other words, GERD phenotypes once determined remain true to form.35,37

Figure 2
Proposed new paradigm for the natural course of NERD.23


Current concepts in the pathophysiology of NERD involve peripheral factors (luminal, mucosal, and sensory afferents) as well as central (psychological, stress, sleep, etc.).

Overall, there is no difference in gastric acid output between NERD patients and those with erosive esophagitis.38 The level of esophageal acid exposure in NERD patients has been examined by Martinez et al.39 The authors demonstrated that only 45.1% of NERD patients had an abnormal pH test compared with 75% of patients with erosive esophagitis and 92.9% of patients with Barrett's esophagus. The mean recorded number of acid reflux events was 95.3 in NERD versus 139.7 in those with erosive esophagitis. Furthermore, patients with NERD had the lowest esophageal acid exposure profile (pH < 4) in % total, recumbent, and upright time as compared to the other GERD groups. In fact, the mean esophageal acid exposure values were only mildly abnormal.40 Unlike patients with erosive esophagitis and Barrett's esophagus who demonstrate intense acid exposure in the very distal portion of the esophagus, NERD patients have very little variation in esophageal acid exposure distribution throughout the esophagus (total and recumbent).41 Shapiro et al. have shown a marked overlap in acid exposure between NERD patients and those with erosive esophagitis and even those with Barrett's esophagus (Table 2).40 This study suggests that other environmental and genetic factors play an important role in disease presentation.

Table 2
The Extent of the Overlap of Esophageal Acid Exposure (time pH < 4) among the Different GERD Groups40

Adachi et al. have demonstrated that NERD patients had significantly lower nighttime esophageal acid exposure as compared to patients with grade C and D erosive esophagitis.42 Dickman et al. have demonstrated that the esophageal acid exposure pattern during sleep is similar among the different GERD groups.43 NERD patients with abnormal pH test had similar level of esophageal acid exposure during sleep as patients with erosive esophagitis. Esophageal acid exposure was the highest at the beginning of sleep and markedly dropped toward the middle of the sleep period.

Several luminal factors were found to be predictors of a sensed acid reflux event as compared to a non-sensed acid reflux event (using impedance + pH sensor), and they include proximal migration of an acid reflux event, larger pH drops, lower pH nadir, larger volume and acid clearance time, preceding higher esophageal cumulative acid exposure time, and presence of gas in the refluxate.44,45 Recently, Schey et al. have shown that NERD patients demonstrated the highest number of acid reflux events before sensed reflux event as compared with other heartburn groups. This suggests that prior sensitization is needed for an acid reflux to be perceived in NERD patients who demonstrated a lower acid exposure compared with erosive esophagitis patients.46 Proximal esophageal migration of a reflux event has been shown to be an important predictor of symptom generation in NERD patients as well as other GERD groups, regardless if the reflux is acidic or weakly acidic.47 The underlying mechanism for this phenomenon is unknown. Some have stipulated that it is likely due to summation effect (the higher the reflux, the more esophageal pain receptors are sensitized) or increased sensitivity of the proximal portion of the esophagus to either chemical or mechanical stimuli.

The role of nonacid reflux in NERD was recently assessed by esophageal impedance-pH monitoring in 150 NERD patients. NERD patients had more reflux episodes (acid and nonacid) as compared to controls. A total of 42% of patients had abnormal esophageal acid exposure as compared to controls. In the subgroup of patients with normal acid exposure, 15% had positive symptom-association probability (SAP) for acid, 12% for non-acid reflux, and 5% for both.48 A recent study conducted in a small group of normal subjects has demonstrated that acidic or weakly acidic solutions can result in the development of dilated intercellular spaces (DIS).49 That suggests that NERD patients are likely to develop similar mucosal abnormalities from both types of gastroesophageal reflux.

There are very limited data concerning the role of bile reflux in symptom generation of patients with NERD. The mean fasting gastric bile acid concentration in NERD patients is similar to healthy controls. Additionally, combined acid and duodenogastroesophageal reflux, which correlates with severity of mucosal involvement in GERD, has been documented in only 50% of NERD patients compared with 79% of erosive esophagitis patients.50

Physiological studies in patients with NERD have revealed minimal esophageal abnormalities. These patients have a slightly higher rate of primary peristalsis failure, defined by non-transmitted contractions or peristaltic contractions that do not traverse the entire esophageal body as compared to normal controls.51 Recently, it has been demonstrated that the rate of triggering secondary peristalsis in patients with NERD was significantly lower than in normal controls. However, when secondary peristalsis did occur in NERD patients, there was no difference in amplitude and velocity when compared to normal controls.51 However, the abnormality in secondary peristalsis may explain the overall homogeneous distribution of acid reflux that was observed by Dickman et al.41 Distal amplitude contractions, as well as mean lower esophageal resting pressure, are mildly reduced in NERD patients as compared with normal subjects. Resting lower esophageal sphincter pressure is rarely below 10 mmHg.20 In contrast, 25% of patients with mild erosive esophagitis and 48% of those with severe erosive esophagitis demonstrate peristaltic dysfunction. The mean resting lower esophageal sphincter pressure is significantly lower in patients with erosive esophagitis as compared to those with NERD.20,38

Hiatal hernia occurs in only the minority of NERD patients. Cameron et al.52 compared hiatal hernia rates in patients with NERD versus those with erosive esophagitis and demonstrated that 29% of the NERD patients had hiatal hernia as compared with 71% of those with erosive esophagitis. The absence of diaphragmatic hernia suggests that transient lower esophageal sphincter relaxation is likely the predominant mechanism for gastroesophageal reflux in most of the NERD patients.53

In most NERD patients, DIS (with a cut-off values of more than 0.56 nm) could be identified using electron micrograph.54 The occurrence of DIS in NERD is attributed to esophageal mucosal exposure to gastroesophageal reflux and possibly even other stimuli.3 Mastracci et al. have demonstrated that Ki 67 nuclear antigen, which is expressed by proliferating cells and provides an objective way to measure the regeneration of squamous epithelium, can serve as a marker that can distinguish NERD patients from normal controls.55

Visceral hypersensitivity has been considered to be an important pathophysiological mechanism in NERD. Three broad mechanisms are believed to underlie visceral hypersensitivity: peripheral sensitization, central sensitization, and psychoneuroimmune interactions.56

In general, assessment of esophageal sensitivity in NERD patients has yielded evidence for reduced perception thresholds for painful stimuli. However, results are difficult to compare due to different sensory testing protocols as well as stimuli. Furthermore, many studies evaluate so-called "NERD patients" without excluding the functional heartburn group.

Miwa and colleagues have specifically evaluated stimulus response functions to acid in patients with NERD, as compared to other GERD groups, using an acid perfusion paradigm.57 The authors demonstrated that NERD patients had lower perception thresholds for pain, especially as compared to normal controls, but also as compared to those with erosive esophagitis and Barrett's esophagus. In a subsequent study, the authors confirmed their previous results but also noted that NERD patients were more sensitive to saline than subjects with erosive esophagitis.58 The authors concluded from this study that NERD patients display a more general esophageal hypersensitivity that is not limited to acidic stimuli only. Even when compared to functional heartburn, NERD patients with abnormal pH testing demonstrated lower perception thresholds for pain using a similar acid perfusion paradigm.59 It has been proposed that the functional heartburn group, as compared to NERD patients, is a heterogeneous group composed of those with esophageal hypersensitivity to acid and others who show no sensitivity to any chemical stimuli. An interesting study has demonstrated that the proximal esophagus in NERD patients is more sensitive to acid perfusion as compared to the distal esophagus.60 The study may provide 1 of the explanations for the strong relationship between proximal esophageal migration of acid reflux and symptoms generation in GERD patients.

Mechanical and thermal stimulation of the esophagus were also assessed in NERD patients. In a study by Reddy et al., the authors used a multimodal stimulation probe to assess pain evoked by either thermal or mechanical stimuli.61 NERD patients demonstrated increased esophageal sensitivity only to heat stimuli but not to cold or mechanical stimuli as compared to normal controls. However, other studies have also demonstrated an increased sensitivity to mechanical stimuli (balloon distention) in NERD patients as compared to the other GERD groups.62

Several receptors have been identified as mediating esophageal hypersensitivity due to acid including up-regulation of acid sensing ion channels, increased expression of TRPV1 receptors (transient receptor potential vanilloid type 1), and prostaglandin E-2 receptor (EP-1).63,64

Various central mechanisms have also been shown to influence processing of afferent signals at the brain level.65 Psychological stresses and emotional perturbation have been demonstrated to potentiate perception of intraesophageal stimuli. By using dichotomous listening, Fass et al. demonstrated that acute laboratory stress increased sensitivity to intraesophageal acid perception in patients with either erosive or nonerosive reflux disease.66 The authors also noted that the increase in perceptual responses to acid was associated with greater emotional response to the stressor. Sleep deprivation has also been shown to induce esophageal hypersensivity to acid perfusion, although the study was carried out only in patients with erosive esophagitis.67

Models for Heartburn in NERD

Several models for heartburn in NERD patients have been proposed. Fass and Tougas suggested that intraesophageal stimuli, either pathologic or physiologic, may lead to symptoms in NERD patients. In their model, the authors emphasized the role of central (through brain-gut interactions) and peripheral (not esophageal) mechanisms in modulating perception of intraesophageal stimuli (Fig. 3).68

Figure 3
The "Fass and Tougas" conceptual model for esophageal symptom generation in NERD.68

Barlow and Orlando proposed the following model to explain the pathophysiology of NERD: DIS enables the diffusion of refluxed gastric acid into the intercellular spaces. Then, acid reaches and activates chemosensitive nociceptors whose signals are transmitted via the dorsal horn of the spinal cord to the brain for symptoms perceptions (Fig. 4).69

Figure 4
The "Barlow and Orlando" suggested model for heartburn in patients with NERD.69

The "Ang, Sifrim and Tack" model combines many of the concepts put forth by the 2 previously mentioned conceptual models (Fig. 5).70 This model emphasizes the value of esophageal hypersensitivity to both mechanical and chemical stimuli.

Figure 5
The "Ang, Sifrim and Tack" model for heartburn in NERD.70

Clinical Characteristics

A large study involving 25 centers in Denmark and Sweden reported on 424 patients with troublesome heartburn associated with NERD. The mean age of the population was 50 yr; 58% were female; only 21% were smokers; 45% were active alcohol users; 53% had more than a 5-year history of heartburn; and only 37% had hiatal hernia documented during upper endoscopy.71 Carlsson et al.16 compared the clinical characteristics of patients with NERD and those with erosive esophagitis. In the NERD group, 60% were female; the mean age was 49 yr; mean weight was 80.5 kg for males and 69.5 kg for females; 23% were smokers; 59% were alcohol consumers; 80% had symptom duration longer than 12 months; 29% had hiatal hernia; and 34% were positive for Helicobacter pylori. The erosive esophagitis group was similar to the NERD group in mean age, smoking and alcohol consumption, prevalence and duration of heartburn, and status of Helicobacter pylori infection. However, there were more males (59%) in the erosive esophagitis group, increased prevalence of hiatal hernia (56%), and increased weight of both males and females (86 kg and 76 kg, respectively).

Increase in body mass index (BMI) is associated with increased risk for having erosive esophagitis.72 Furthermore, obese patients (BMI ≥ 30 kg/m2) demonstrate a higher prevalence of erosive esophagitis (26.5%) as compared to normal-weight subjects (9.3%).73 The effect of metabolic risk factors on the natural history of GERD was quantified in a large population undergoing repeated endoscopy. Being male, smoking, or having metabolic syndrome independently increased the likelihood of progression from NERD to erosive esophagitis.74

Psychological comorbidities in GERD patients have been shown to predict the presence of GERD-related symptoms regardless of the presence or absence of esophageal mucosal injury.75-77 Patients with higher emotional sensitivity or neuroticism complain more frequently of GERD symptoms such as heartburn. However, studies did not find a specific correlation between psychological comorbidity and esophageal mucosal damage or extent of esophageal acid exposure.78

A recent study by Wu et al.79 evaluated the clinical characteristics of patients with NERD in comparison to those with erosive esophagitis. Each patient underwent endoscopy, esophageal manometry, acid perfusion test, and ambulatory 24-hour esophageal pH monitoring. The authors found that NERD patients had a significantly higher prevalence of functional bowel disorders such as functional dyspepsia and irritable bowel syndrome, psychological disorders, and positive acid perfusion test. Patients with erosive esophagitis were characterized by higher prevalence of hiatal hernia, greater esophageal acid exposure, and more esophageal dysmotility.

Irritable bowel syndrome (IBS) like symptoms as well as dyspepsia-like symptoms are very commonly reported by NERD patients.79,80 However, the association with functional bowel symptoms is not distinctive to NERD and is also very common in erosive esophagitis patients. These symptoms were demonstrated to independently determine reflux symptoms severity in NERD patients as compared to normal controls.81 In a study comparing NERD and functional heartburn patients, bowel symptoms were similarly scored by both groups, but the severity of reflux symptoms was independently associated with the bowel symptoms.82

Clinical studies have demonstrated that heartburn severity and intensity are similar in patients with erosive esophagitis and those with NERD.83 Additionally, the impact of heartburn severity on patients' quality of life was similar in both GERD groups as well.16,84 Furthermore, sleep dysfunction is similar between patients with NERD and those with erosive esophagitis.85


Upper endoscopy is the most sensitive diagnostic tool for assessing GERD-related esophageal mucosal injury such as erosions, ulceration, stricture, Barrett's esophagus, and others. However, uncertainty in detecting mucosal breaks and in describing their severity can lead to inconsistency among different endoscopists. This is particularly essential in diagnosing NERD because of the need to demonstrate normal endoscopic examination of the esophageal mucosa. However, several recent studies using high resolution magnification endoscopy demonstrated the presence of minimal mucosal changes at the squamocolumnar junction of GERD patients with normal conventional upper endoscopy. The changes included vascular injection or vascular spots above the Z-line, villous mucosal surface, mucosal islands, and microerosions.86 Others have added Lugol chromoendoscopy to further evaluate NERD patients for minimal esophageal changes at the squamocolumnar junction. Visible unstained streaks by Lugol chromoendoscopy were considered indicative of mucosal injury (as was further substantiated by biopsy).87

Recently, narrow-band imaging (NBI) was introduced for better visualization of mucosal and microvascular patterns at the esophagogastric junction of NERD patients with normal endoscopy. This technique utilizes spectral narrow band filters and enables imaging of superficial tissue structures such as capillary and mucosal patterns without the use of dye. Sharma et al. demonstrated that the presence of microerosions and increased vascularity at the squamocolumnar junction were the best predictors for GERD diagnosis. These results were further confirmed when subgroup analysis of NERD and erosive esophagitis was compared separately to controls. Although the interobserver agreement for various NBI findings was very good, the intraobserver agreement was modest.88 A subsequent study demonstrated that the intra-and interobserver reproducibility in grading esophageal mucosal changes could be improved when NBI was applied together with conventional imaging. This additional benefit appeared to derive from better depiction of small erosions.89

As a result of the aforementioned and other studies, the term "minimal change esophagitis" was introduced, and further studies claimed that these mucosal changes can be detected in many patients with NERD.90 Consequently, some authors went further and proposed that NERD patients with normal conventional endoscopy, but with minimal changes at the squamocolumnar junction during magnification endoscopy, chromoendoscopy or NBI, should be considered as having erosive esophagitis. However, there were no attempts to correlate minimal mucosal changes with esophageal physiological abnormalities and to show that these patients are truly closer to erosive esophagitis than to NERD. In addition, the clinical implications of these findings remain to be elucidated. One study has already demonstrated that patients with the so-called "minimal change esophagitis" have different physiological characteristics than patients with erosive esophagitis.90 Furthermore, concerns have been raised about the inter-and intraobserver variability of these minute lesions. Thus, the value of documenting minimal mucosal changes in NERD patients is presently unclear. Furthermore, the yield of identifying these lesions should be weighed against the cost of the needed equipment and the availability of more economical strategies to handle these patients.

Distinguishing NERD patients from those with eosinophilic esophagitis has become a major area of interest in the past few years. Whilst most of those with classic GERD symptoms are unlikely to have eosinophilic esophagitis, it is those who appear to have some of the clinical and anatomic features of eosinophilic esophagitis who have been the focus of investigation if GERD is the direct underlying cause.91 Recently, Dellon et al. compared clinical, endoscopic, and histologic findings between eosinophilic esophagitis and GERD.92 Unconditional logistic regression was performed to develop a model to predict eosinophilic esophagitis, and receiver operator characteristic curves were constructed. The authors found that, as compared with GERD, features that independently predict eosinophilic esophagitis included younger age, dysphagia, food allergy, esophageal rings, linear furrows, white plaques or exudate, absence of hiatal hernia, a higher maximum eosinophil count, and the presence of eosinophil degranulation in the biopsy specimen. The area under the curve for this model was 0.934.

Ambulatory 24-hour esophageal pH monitoring is essential for diagnosing NERD, especially after the recent introduction of the new definitions for functional heartburn by the Rome III Committee for Functional Esophageal Disorders.10 However, the test is not commonly done in practice, and response to PPI treatment has been used instead to identify the functional heartburn patients.93-95 Esophageal impedance + pH has been used extensively to primarily study patients who failed PPI treatment. By using this technique, patients who are not responsive to PPI treatment (up to twice daily) have more than a 50% chance of having functional heartburn.96 However, the role of impedance + pH in nontreated GERD patients, and more specifically in those with NERD, is likely to be very limited.3


PPIs are currently considered the most effective and safe therapeutic modality for GERD. In clinical trials, these agents have consistently been demonstrated to be more effective than any other acid-suppressant agent in healing erosive esophagitis and relieving GERD-related symptoms. The superior efficacy of PPIs is also observed in NERD patients. In a recent meta-analysis, van Pinxteren et al. demonstrated that the relative risk (RR) for heartburn remission in placebo-controlled trials of patients with NERD was 0.68 (95% CI: 0.59-0.78) for PPIs versus placebo and 0.84 (95% CI: 0.74-0.95) for H2RA versus placebo.97 The relative risk for PPIs versus H2RAs was 0.74 (95% CI: 0.53-1.03).

A number of studies evaluated the efficacy of PPIs in NERD patients. In a multicenter, randomized, double-blind study, omeprazole 20 mg once daily was compared with placebo in controlling symptoms of 209 patients with NERD.98 After 4 weeks of therapy, 57% of patients in the omeprazole group were free of heartburn, 75% were free of acid regurgitation, and 43% were completely asymptomatic. In another study, NERD patients were randomized to omeprazole 20 mg/day, omeprazole 10 mg/day, or placebo.13 The study authors found that at 4 weeks, 46% of patients treated with omeprazole 20 mg/day, 31% treated with omeprazole 10 mg/day, and 13% of those who received placebo reported complete relief of heartburn. Miner et al. enrolled 203 patients with NERD who were randomized to either rabeprazole 20 mg once daily or placebo. After 4 weeks, 56.7% of the patients receiving rabeprazole reported satisfactory symptom relief when compared with 32.2% of those receiving placebo (p<0.008).99 A recent study that utilized the wireless pH capsule has demonstrated that PPIs can normalize esophageal acid exposure in patients with NERD within 48 hours after initial administration.100

In general, the proportion of NERD patients responding to a standard dose of PPI is approximately 20-30% lower than what has been documented in patients with erosive esophagitis. In a systematic review of the literature, PPI symptomatic response pooled rate was 36.7% (95% CI: 34.1-39.3) in NERD patients and 55.5% (95% CI: 51.5-59.5) in those with erosive esophagitis.101 Therapeutic gain was 27.5% in NERD as compared with 48.9% in erosive esophagitis. Moreover, patients with NERD demonstrate a close relationship between response to PPI therapy and degree of esophageal acid exposure. The greater the distal esophageal acid exposure, the higher the proportion of NERD patients reporting symptom resolution.13 This is the opposite of what has been observed in patients with erosive esophagitis, where increased esophageal inflammation has been associated with lower response rate to PPI once daily. Patients with NERD also demonstrate longer lag time to sustained symptom response when compared to patients with erosive esophagitis (2 to 3-fold). Furthermore, patients with NERD demonstrate similar symptomatic response to half and full standard dose of PPI,102 unlike patients with erosive esophagitis who demonstrate an incremental increase in healing and symptom resolution. In 1 study, the time to first and sustained relief of reflux symptoms during PPI treatment was assessed by the ReQuest™ questionnaire in NERD patients. Both pantoprazole (20 mg/day) and esomeprazole (20 mg/day) have been shown to provide a similar median time to first symptom relief (2 days) and to sustained symptom relief (10-13 days).103 The reason for the differences in therapeutic response parameters between NERD and erosive esophagitis is primarily due to the common inclusion of functional heartburn subjects in the NERD group. However, because most NERD patients demonstrate only modest abnormal esophageal acid exposure, even after excluding functional heartburn patients, the symptomatic response rate of NERD patients to PPI remains lower that what has been observed in erosive esophagitis patients.

Because GERD is mostly not a progressive disorder, treatment for many of these patients could be symptom driven. Thus, on-demand or intermittent therapy with a PPI is an attractive therapeutic strategy for NERD patients in clinical practice.104,105 These therapeutic approaches are convenient, allow patients to remain in control, cost effective, and decrease the likelihood of rebound of acid secretion. Studies have demonstrated that intermittent or on-demand PPI therapy in NERD is effective and associated with improved quality of life as well as reduced cost.106,107

Dexlansoprazole MR is a novel, modified-release formulation of dexlansoprazole, which incorporates dual delayed-release technology designed to prolong the serum concentration-time profile, and thus provides extended acid-suppression, has been recently assessed in NERD patients. Dexlansoprazole 30 mg/day for 4 weeks was shown to be superior to placebo in providing 24-hour heartburn-free days and nights (54.9% vs. 17.5% and 80.8% vs. 51.7%, respectively).108

Novel therapeutic modalities are currently under consideration for GERD patients and specifically those with NERD. The main areas of interest include improving acid suppression, reducing the transient lower esophageal sphincter relaxation rate, decreasing esophageal sensitivity, and enhancing esophageal motility.

Response to antireflux surgery has been shown to be different between patients with NERD versus those with erosive esophagitis. Fenton et al. compared the clinical outcome of anti-reflux surgery in patients with erosive esophagitis versus those with NERD, demonstrating that 91% versus 56% reported heartburn resolution, 24% versus 50% reported dysphagia post-surgery and 94% versus 79% were satisfied with surgery, respectively.109


NERD is the most common phenotypic presentation of GERD. Whilst separating between erosive esophagitis and NERD on a clinical level is a very difficult task, there are clearly physiological, pathophysiological, anatomical, and even histological characteristics that are unique to NERD. Natural course studies demonstrate that most NERD patients will not progress over time to erosive esophagitis or even Barrett's oesophagus. NERD patients as compared to those with erosive esophagitis demonstrate a highly variable and unpredictable symptomatic response rate to antireflux treatment. This is likely to explain the high percentage of NERD patients among those who failed PPI treatment.


Financial support: None.

Conflicts of interest: None.


1. Fass R, Fennerty MB, Vakil N. Nonerosive reflux disease - current concepts and dilemmas. Am J Gastroenterol. 2001;96:303–314. [PubMed]
2. Locke GR, 3rd, Talley NJ, Fett SL, Zinsmeister AR, Melton LJ., 3rd Prevalence and clinical spectrum of gastroesophageal reflux: a population-based study in Olmsted County, Minnesota. Gastroenterology. 1997;112:1448–1456. [PubMed]
3. Fass R, Sifrim D. Management of heartburn not responding to proton pump inhibitors. Gut. 2009;58:295–309. [PubMed]
4. Fass R. Proton pump inhibitor failure--what are the therapeutic options? Am J Gastroenterol. 2009;104(suppl 2):S33–S38. [PubMed]
5. Dent J, Brun J, Fendrick A, et al. An evidence-based appraisal of reflux disease management--the Genval Workshop Report. Gut. 1999;44(suppl 2):S1–S16. [PMC free article] [PubMed]
6. Vakil N, van Zanten SV, Kahrilas P, Dent J, Jones R. The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus. Am J Gastroenterol. 2006;101:1900–1920. [PubMed]
7. Martinez SD, Malagon IB, Garewal HS, Cui H, Fass R. Non-erosive reflux disease (NERD) - acid reflux and symptom patterns. Aliment Pharmacol Ther. 2003;17:537–545. [PubMed]
8. Clouse RE, Richter JE, Heading RC, Janssens J, Wilson JA. Functional esophageal disorders. In: Drossman D, editor. Rome II: the functional gastrointestinal disorders. 2nd ed. Lawrence, KS: Allen Press, Inc; 2000. p. 275.
9. Watson RG, Tham TC, Johnston BT, McDougall NI. Double blind cross-over placebo controlled study of omeprazole in the treatment of patients with reflux symptoms and physiological levels of acid reflux - the "sensitive oesophagus". Gut. 1997;40:587–590. [PMC free article] [PubMed]
10. Drossman D. Rome III: The functional gastrointestinal disorders. 3rd ed. McLean, VA: Degnon Associates, Inc; 2006. pp. 369–418.
11. Winters C, Jr, Spurling TJ, Chobanian SJ, et al. Barrett's esophagus: A prevalent, occult complication of gastroesophageal reflux disease. Gastroenterology. 1987;92:118–124. [PubMed]
12. Johansson KE, Ask P, Boeryd B, Fransson SG, Tibbling L. Oesophagitis, signs of reflux, and gastric acid secretion in patients with symptoms of gastro-oesophageal reflux disease. Scand J Gastroenterol. 1986;21:837–847. [PubMed]
13. Lind T, Havelund T, Carlsson R, et al. Heartburn without oesophagitis: efficacy of omeprazole therapy and features determining therapeutic response. Scand J Gastroenterol. 1997;32:974–979. [PubMed]
14. Jones RH, Hungin AP, Phillips J, et al. Gastro-esophageal reflux disease in primary care in Europe: clinical presentation and endoscopic findings. Eur J Gen Pract. 1995;1:149–154.
15. Galmiche JP, Barthelemy P, Hamelin B. Treating the symptoms of gastro-oesophageal reflux disease: a double-blind comparison of omeprazole and cisapride. Aliment Pharmacol Ther. 1997;11:765–773. [PubMed]
16. Carlsson R, Dent J, Watts R, et al. International GORD Study Group. Gastro-oesophageal reflux disease in primary care: an international study of different treatment strategies with omeprazole. Eur J Gastroenterol Hepatol. 1998;10:119–124. [PubMed]
17. Robinson M, Earnest D, Rodriguez-Stanley S, et al. Heartburn requiring frequent antacid use may indicate significant illness. Arch Intern Med. 1998;158:2373–2376. [PubMed]
18. Ronkainen J, Aro P, Storskrubb T, et al. High prevalence of gastroesophageal reflux symptoms and esophagitis with or without symptoms in the general adult Swedish population: a Kalixanda study report. Scand J Gastroenterol. 2005;40:275–285. [PubMed]
19. Zagari RM, Fuccio L, Wallander MA, et al. Gastro-oesophageal reflux symptoms, oesophagitis and Barrett's oesophagus in the general population: the Loiano-Monghidoro study. Gut. 2008;57:1354–1359. [PubMed]
20. Quigley EM. Gastro-oesophageal reflux disease - spectrum or continuum? QJM. 1997;90:75–78. [PubMed]
21. Fass R. Erosive esophagitis and nonerosive reflux disease (NERD): comparison of epidemiologic, physiologic, and therapeutic characteristics. J Clin Gastroenterol. 2007;41:131–137. [PubMed]
22. Fass R, Ofman J. Gastroesophageal reflux disease--should we adopt a new conceptual framework? Am J Gastroenterol. 2002;97:1901–1909. [PubMed]
23. Fass R. Non-erosive reflux disease (NERD) and erosive esophagitis--a spectrum of disease or special entities? Z Gastroenterol. 007;45:1156–1163. [PubMed]
24. Pace F, Santalucia F, Bianchi Porro G. Natural history of gastro-oesophageal reflux disease without oesophagitis. Gut. 1991;32:845–848. [PMC free article] [PubMed]
25. Kuster E, Ros E, Toledo-Pimentel V, et al. Predictive factors of the long term outcome in gastro-oesophageal reflux disease: six year follow up of 107 patients. Gut. 1994;35:8–14. [PMC free article] [PubMed]
26. Isolauri J, Luostarinen M, Isolauri E, Reinikainen O, Viljakka M, Keyrilainen O. Natural course of gastroesophageal reflux disease: 17-22 year follow-up of 60 patients. Am J Gastroenterol. 1997;92:37–41. [PubMed]
27. McDougall NI, Johnston BT, Kee F, Collins JS, McFarland RJ, Love AH. Natural history of reflux oesophagitis: a 10 year follow up of its effect on patient symptomatology and quality of life. Gut. 1996;38:481–486. [PMC free article] [PubMed]
28. McDougall NI, Johnston BT, Collins JS, McFarland RJ, Love AH. Disease progression in gastro-oesophageal reflux disease as determined by repeat oesophageal pH monitoring and endoscopy 3 to 4.5 years after diagnosis. Eur J Gastroenterol Hepatol. 1997;9:1161–1167. [PubMed]
29. Manabe N, Yoshihara M, Sasaki A, Tanaka S, Haruma K, Chayama K. Clinical characteristics and natural history of patients with low-grade reflux esophagitis. J Gastroenterol Hepatol. 2002;17:949–954. [PubMed]
30. Pace F, Bollani S, Molteni P, Bianchi Porro G. Natural history of gastro-oesophageal reflux disease without oesophagitis (NERD)--a reappraisal 10 years on. Dig Liver Dis. 2004;36:111–115. [PubMed]
31. Pace F, Bianchi Porro G. Gastroesophageal reflux disease: a typical spectrum disease (a new conceptual framework is not needed) Am J Gastroenterol. 2004;99:946–949. [PubMed]
32. Labenz J, Nocon M, Lind T, et al. Prospective follow-up data from the ProGERD study suggest that GERD is not a categorical disease. Am J Gastroenterol. 2006;101:2457–2462. [PubMed]
33. Willich S, Nocon M, Kulig M, et al. Cost-of-disease analysis in patients with gastro-oesophageal reflux disease and Barrett's mucosa. Aliment Pharmacol Ther. 2006;23:371–376. [PubMed]
34. Garrido Serrano A, Guerrero Igea FJ, Lepe Jiménez JA, Perianes Hernández C. Clinical features and endoscopic progression of gastroesophageal reflux disease. Rev Esp Enferm Dig. 2003;95:712–716. 707–711. [PubMed]
35. Sontag SJ, Sonnenberg A, Schnell TG, Leya J, Metz A. The long-term natural history of gastroesophageal reflux disease. J Clin Gastroenterol. 2006;40:398–404. [PubMed]
36. Bardhan KD, Royston C, Nayyar AK. Reflux rising! An essay on witnessing a disease in evolution. Dig Liver Dis. 2006;38:163–168. [PubMed]
37. Agrawal A, Castell D. GERD is chronic but not progressive. J Clin Gastroenterol. 2006;40:374–375. [PubMed]
38. Ho KY, Kang JY. Reflux esophagitis patients in Singapore have motor and acid exposure abnormalities similar to patients in the Western hemisphere. Am J Gastroenterol. 1999;94:1186–1191. [PubMed]
39. Martinez SD, Malagon I, Garewal HS, Fass R. Non-erosive reflux disease (NERD) - is it really just a mild form of gastroesophageal reflux disease (GERD) [abstract]? Gastroenterology. 2001;120(suppl 1):A424.
40. Shapiro M, Green C, Faybush EM, Esquivel RF, Fass R. The extent of oesophageal acid exposure overlap among the different gastro-oesophageal reflux disease groups. Aliment Pharmacol Ther. 2006;23:321–329. [PubMed]
41. Dickman R, Bautista JM, Wong WM, et al. Comparison of esophageal acid exposure distribution along the esophagus among the different gastroesophageal reflux disease (GERD) groups. Am J Gastroenterol. 2006;101:2463–2469. [PubMed]
42. Adachi K, Fujishiro H, Katsube T, et al. Predominant nocturnal acid reflux in patients with Los Angeles grade C and D reflux esophagitis. J Gastroenterol Hepatol. 2001;16:1191–1196. [PubMed]
43. Dickman R, Parthasarathy S, Malagon IB, et al. Comparisons of the distribution of oesophageal acid exposure throughout the sleep period among the different gastro-oesophageal reflux disease groups. Aliment Pharmacol Ther. 2007;26:41–48. [PubMed]
44. Bredenoord AJ, Weusten BL, Curvers WL, Timmer R, Smout AJ. Determinants of perception of heartburn and regurgitation. Gut. 2006;55:313–318. [PMC free article] [PubMed]
45. Emerenziani S, Sifrim D, Habib FI, et al. Presence of gas in the refluxate enhances reflux perception in non-erosive patients with physiological acid exposure of the oesophagus. Gut. 2008;57:443–447. [PubMed]
46. Schey R, Shapiro M, Navarro-Rodriguez T, et al. Comparison of the different characteristics of sensed reflux events among different heartburn groups. J Clin Gastroenterol. 2009;43:699–704. [PubMed]
47. Emerenziani S, Ribolsi M, Sifrim D, Blondeau K, Cicala M. Regional oesophageal sensitivity to acid and weakly acidic reflux in patients with non-erosive reflux disease. Neurogastroenterol Motil. 2009;21:253–258. [PubMed]
48. Savarino E, Zentilin P, Tutuian R, et al. The role of nonacid reflux in NERD: lessons learned from impedance-pH monitoring in 150 patients off therapy. Am J Gastroenterol. 2008;103:2685–2693. [PubMed]
49. Farre R, Fornari F, Blondeau K, et al. Acid and weakly acidic solutions impair mucosal integrity of distal exposed and proximal non-exposed human oesophagus. Gut. 2010 (In press) [PubMed]
50. Vaezi MF, Richter JE. Role of acid and duodenogastroesophageal reflux in gastroesophageal reflux disease. Gastroenterology. 1996;111:1192–1199. [PubMed]
51. Iwakiri K, Hayashi Y, Kotoyori M, et al. Defective triggering of secondary peristalsis in patients with non-erosive reflux disease. J Gastroenterol Hepatol. 2007;22:2208–2211. [PubMed]
52. Cameron AJ. Barrett's esophagus: prevalence and size of hiatal hernia. Am J Gastroenterol. 1999;94:2054–2059. [PubMed]
53. van Herwaarden MA, Samsom M, Smout AJ. Excess gastroesophageal reflux in patients with hiatus hernia is caused by mechanisms other than transient LES relaxations. Gastroenterology. 2000;119:1439–1446. [PubMed]
54. Dent J. Microscopic esophageal mucosal injury in nonerosive reflux disease. Clin Gastroenterol Hepatol. 2007;5:4–16. [PubMed]
55. Mastracci L, Grillo F, Zentilin P, et al. Cell proliferation of squamous epithelium in gastro-oesophageal reflux disease: correlations with clinical, endoscopic and morphological data. Aliment Pharmacol Ther. 2007;25:637–645. [PubMed]
56. Knowles CH, Aziz Q. Visceral hypersensitivity in non-erosive reflux disease. Gut. 2008;57:674–683. [PubMed]
57. Miwa H, Minoo T, Hojo M, et al. Oesophageal hypersensitivity in Japanese patients with non-erosive gastro-oesophageal reflux diseases. Aliment Pharmacol Ther. 2004;20(suppl 1):112–117. [PubMed]
58. Nagahara A, Miwa H, Minoo T, et al. Increased esophageal sensitivity to acid and saline in patients with nonerosive gastro-esophageal reflux disease. J Clin Gastroenterol. 2006;40:891–895. [PubMed]
59. Shapiro M, Green C, Bautista JM, et al. Functional heartburn patients demonstrate traits of functional bowel disorder but lack a uniform increase of chemoreceptor sensitivity to acid. Am J Gastroenterol. 2006;101:1084–1091. [PubMed]
60. Thoua NM, Khoo D, Kalantzis C, Emmanuel AV. Acid-related oesophageal sensitivity, not dysmotility, differentiates subgroups of patients with non-erosive reflux disease. Aliment Pharmacol Ther. 2008;27:396–403. [PubMed]
61. Reddy H, Staahl C, Arendt-Nielsen L, Gregersen H, Drewes AM, Funch-Jensen P. Sensory and biomechanical properties of the esophagus in non-erosive reflux disease. Scand J Gastroenterol. 2007;42:432–440. [PubMed]
62. Trimble KC, Pryde A, Heading RC. Lowered oesophageal sensory thresholds in patients with symptomatic but not excess gastro-oesophageal reflux: evidence for a spectrum of visceral sensitivity in GORD. Gut. 1995;37:7–12. [PMC free article] [PubMed]
63. Bhat YM, Bielefeldt K. Capsaicin receptor (TRPV1) and non-erosive reflux disease. Eur J Gastroenterol Hepatol. 2006;18:263–270. [PubMed]
64. Sarkar S, Hobson AR, Hughes A, et al. The prostaglandin E2 receptor-1 (EP-1) mediates acid-induced visceral pain hypersensitivity in humans. Gastroenterology. 2003;124:18–25. [PubMed]
65. Anand P, Aziz Q, Willert R, van Oudenhove L. Peripheral and central mechanisms of visceral sensitization in man. Neurogastroenterol Motil. 2007;19:29–46. [PubMed]
66. Fass R, Naliboff BD, Fass SS, et al. The effect of auditory stress on perception of intraesophageal acid in patients with GERD. Gastroenterology. 2008;134:696–705. [PubMed]
67. Schey R, Dickman R, Parthasarathy S, et al. Sleep deprivation is hyperalgesic in patients with gastroesophageal reflux disease. Gastroenterology. 2007;133:1787–1795. [PubMed]
68. Fass R, Tougas G. Functional heartburn: the stimulus, the pain, and the brain. Gut. 2002;51:885–892. [PMC free article] [PubMed]
69. Barlow WJ, Orlando RC. The pathogenesis of heartburn in non-erosive reflux disease: a unifying hypothesis. Gastroenterology. 2005;128:771–778. [PubMed]
70. Ang D, Sifrim D, Tack J. Mechanisms of heartburn. Nat Clin Pract Gastroenterol Hepatol. 2008;5:383–392. [PubMed]
71. Lind T, Havelund T, Lundell L, et al. On demand therapy with omeprazole for the long-term management of patients with heartburn without oesophagitis - a placebo-controlled randomized trial. Aliment Pharmacol Ther. 1999;13:907–914. [PubMed]
72. Hampel H, Abraham NS, El-Serag HB. Meta-analysis: obesity and the risk of gastroesophageal reflux disease and its complications. Ann Intern Med. 2005;143:199–211. [PubMed]
73. Aro P, Ronkainen J, Talley NJ, Storskrubb T, Bolling-Sternevald E, Agreus L. Body mass index and chronic unexplained gastrointestinal symptoms: an adult endoscopic population based study. Gut. 2005;54:1377–1383. [PMC free article] [PubMed]
74. Lee YC, Yen AM, Tai JJ, et al. The effect of metabolic risk factors on the natural course of gastro-oesophageal reflux disease. Gut. 2009;58:174–181. [PMC free article] [PubMed]
75. Mayer EA. The neurobiology of stress and gastrointestinal disease. Gut. 2000;47:861–869. [PMC free article] [PubMed]
76. Richter JE, Bradley LC. Psychophysiological interactions in esophageal diseases. Semin Gastrointest Dis. 1996;7:169–184. [PubMed]
77. Nielzen S, Pettersson KI, Regnell G, Svensson R. The role of psychiatric factors in symptoms of hiatus hernia or gastric reflux. Acta Psychiatr Scand. 1986;73:214–220. [PubMed]
78. Lee YC, Wang HP, Chiu HM, et al. Comparative analysis between psychological and endoscopic profiles in patients with gastroesophageal reflux disease: a prospective study based on screening endoscopy. J Gastroenterol Hepatol. 2006;21:798–804. [PubMed]
79. Wu JC, Cheung CM, Wong VW, Sung JJ. Distinct clinical characteristics between patients with nonerosive reflux disease and those with reflux esophagitis. Clin Gastroenterol Hepatol. 2007;5:690–695. [PubMed]
80. Kahrilas PJ, Miner P, Johanson J, Mao L, Jokubaitis L, Sloan S. Efficacy of rabeprazole in the treatment of symptomatic gastroesophageal reflux disease. Dig Dis Sci. 2005;50:2009–2018. [PubMed]
81. Zimmerman J, Hershcovici T. Bowel symptoms in nonerosive gastroesophageal reflux disease: nature, prevalence, and relation to acid reflux. J Clin Gastroenterol. 2008;42:261–265. [PubMed]
82. Hershcovici T, Zimmerman J. Functional heartburn vs. non-erosive reflux disease: similarities and differences. Aliment Pharmacol Ther. 2008;27:1103–1109. [PubMed]
83. Smout AJPM. Endoscopy-negative acid reflux disease. Aliment Pharmacol Ther. 1997;11:81–85.
84. Venables TL, Newland RD, Patel AC, Hole J, Wilcock C, Turbitt ML. Omeprazole 10 milligrams once daily; omeprazole 20 mg milligrams once daily, or ranitidine 150 milligrams twice daily, evaluated as initial therapy for the relief of symptoms of gastro-oesophageal reflux disease in general practice. Scand J Gastroenterol. 1997;32:965–973. [PubMed]
85. Yi CH, Hu CT, Chen CL. Sleep dysfunction in patients with GERD: erosive versus nonerosive reflux disease. Am J Med Sci. 2007;334:168–170. [PubMed]
86. Kiesslich R, Kanzler S, Vieth M, et al. Minimal change esophagitis: prospective comparison of endoscopic and histological markers between patients with non-erosive reflux disease and normal controls using magnifying endoscopy. Dig Dis. 2004;22:221–227. [PubMed]
87. Yoshikawa I, Yamasaki M, Yamasaki T, Kume K, Otsuki M. Lugol chromoendoscopy as a diagnostic tool in so-called endoscopy-negative GERD. Gastrointest Endosc. 2005;62:698–703. [PubMed]
88. Sharma P, Wani S, Bansal A, et al. A feasibility trial of narrow band imaging endoscopy in patients with gastroesophageal reflux disease. Gastroenterology. 2007;133:454–464. [PubMed]
89. Lee YC, Lin JT, Chiu HM, et al. Intraobserver and interobserver consistency for grading esophagitis with narrow-band imaging. Gastrointest Endosc. 2007;66:230–236. [PubMed]
90. Nakamura T, Shirakawa K, Masuyama H, Sugaya H, Hiraishi H, Terano A. Minimal change oesophagitis: a disease with characteristic differences to erosive oesophagitis. Aliment Pharmacol Ther. 2005;21:19–26. [PubMed]
91. Spechler SJ, Genta RM, Souza RF. Thoughts on the complex relationship between gastroesophageal reflux disease and eosinophilic esophagitis. Am J Gastroenterol. 2007;102:1301–1306. [PubMed]
92. Dellon ES, Gibbs WB, Fritchie KJ, et al. Clinical, endoscopic, and histologic findings distinguish eosinophilic esophagitis from gastroesophageal reflux disease. Clin Gastroenterol Hepatol. 2009;7:1305–1313. [PMC free article] [PubMed]
93. Fass R, Ofman J, Gralnek I, et al. Clinical and economic assessment of the omeprazole test in patients with symptoms suggestive of gastroesophageal reflux disease. Arch Intern Med. 1999;159:2161–2168. [PubMed]
94. Gasiorowska A, Fass R. The proton pump inhibitor (PPI) test in GERD: does it still have a role? J Clin Gastroenterol. 2008;42:867–874. [PubMed]
95. Fass R, Gasiorowska A. Refractory GERD: what is it? Curr Gastroenterol Rep. 2008;10:252–257. [PubMed]
96. Mainie I, Tutuian R, Shay S, et al. Acid and non-acid reflux in patients with persistent symptoms despite acid suppressive therapy: a multicentre study using combined ambulatory impedance-pH monitoring. Gut. 2006;55:1398–1402. [PMC free article] [PubMed]
97. van Pinxteren B, Numans ME, Bonis PA, Lau J. Short-term treatment with proton pump inhibitors, H2-receptor antagonists and prokinetics for gastro-oesophageal reflux disease-like symptoms and endoscopy negative reflux disease. Cochrane Database Syst Rev. 2004;18:CD002095. [PubMed]
98. Bate CM, Griffin SM, Keeling PW, et al. Reflux symptom relief with omeprazole in patients without unequivocal oesophagitis. Aliment Pharmacol Ther. 1996;10:547–555. [PubMed]
99. Miner P, Jr, Orr W, Filippone J, Jokubaitis L, Sloan S. Rabeprazole in nonerosive gastroesophageal reflux disease: a randomized placebo-controlled trial. Am J Gastroenterol. 2002;97:1332–1339. [PubMed]
100. Calabrese C, Liguori G, Gabusi V, et al. Ninety-six-hour wireless oesophageal pH monitoring following proton pump inhibitor administration in NERD patients. Aliment Pharmacol Ther. 2008;28:250–255. [PubMed]
101. Dean BB, Gano AD, Jr, Knight K, Ofman JJ, Fass R. Effectiveness of proton pump inhibitors in nonerosive reflux disease. Clin Gastroenterol Hepatol. 2004;2:656–664. [PubMed]
102. Richter JE, Campbell DR, Kahrilas PJ, Huang B, Fludas C. Lansoprazole compared with ranitidine for the treatment of non-erosive gastroesophageal reflux disease. Arch Intern Med. 2000;160:1803–1809. [PubMed]
103. Monnikes H, Pfaffenberger B, Gatz G, Hein J, Bardhan KD. Novel measurement of rapid treatment success with ReQuest: first and sustained symptom relief as outcome parameters in patients with endoscopy-negative GERD receiving 20 mg pantoprazole or 20 mg esomeprazole. Digestion. 2005;71:152–158. [PubMed]
104. Bytzer P, Blum A, De Herdt D, Dubois D. Six-month trial of on-demand rabeprazole 10 mg maintains symptom relief in patients with non-erosive reflux disease. Aliment Pharmacol Ther. 2004;20:181–188. [PubMed]
105. Juul-Hansen P, Rydning A. On-demand requirements in patient with endoscopy-negative GERD: H2-blocker versus PPI. Aliment Pharmacol Ther. 2009;29:207–212. [PubMed]
106. Wiklund I, Bardhan KD, Muller-Lissner S, et al. The European Study Group. Quality of life during acute and intermittent treatment of gastro-oesophageal reflux disease with omeprazole compared with ranitidine. Results from a multicentre clinical trial. Ital J Gastroenterol Hepatol. 1998;30:19–27. [PubMed]
107. Gerson LB, Robbins AS, Garbert A, Hornberger J, Triadafilopoulas G. A cost-effectiveness analysis of prescribing strategies in the management of gastroesophageal reflux disease. Am J Gastroenterol. 2000;95:395–407. [PubMed]
108. Fass R, Chey WD, Zakko SF, et al. Clinical trial: the effects of the proton pump inhibitor dexlansoprazole MR on daytime and nighttime heartburn in patients with non-erosive reflux disease. Aliment Pharmacol Ther. 2009;29:1261–1272. [PubMed]
109. Fenton P, Terry ML, Galloway KD, Smith CD, Hunter JG, Waring JP. Is there a role for laparoscopic fundoplication in patients with non-erosive reflux disease (NERD) [abstract]? Gastroenterology. 2000;118(suppl 2):A481.

Articles from Journal of Neurogastroenterology and Motility are provided here courtesy of The Korean Society of Neurogastroenterology and Motility